





**AMENDMENTS**

**In the Claims:**

Claims 1-2. (Canceled).

3. (Previously presented) The compound or compounds according to claim 34, selected from the group consisting of the compounds of formulae Ia, Ib, Ic and Id,





wherein



$R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $X$ ,  $Y$ ,  $p$  and  $q$  and are as defined in claim 34,  
or tautomeric forms thereof, salts and stereoisomers thereof or mixtures  
thereof in all ratios.

4. (Canceled).
5. (Previously presented) The compound or compounds according to claim 34, having formula A-CO-NH-B, wherein A- and -B are selected from the group consisting of



A- -B

---



(1)





(2)





(3)





(4)





(5)





(6)





(7)





(8)





(9)





(10)





(11)





(12)





(13)





(14)





(15)





(16)





(17)





(18)





(19)





(20)





(21)





(22)

















(23)




(24)







(32)




(33)




(34)





(35)





(36)





(37)





(38)





(39)





(40)




(41)





(42)




(43)

















(44)




(45)







(53)




(54)



(55)




(56)











(57)




(58)




(59)




(60)




(61)




(62)





(63)




(64)





(65)





(66)





(67)





(68)





(69)





(70)





(71)





(72)





(73)





(74)





(75)





(76)





(77)





(78)





(79)





(80)





(81)





(82)





(83)





(84)





(85)





(86)





(87)





(88)





(89)





(90)





(91)





(92)





(93)





(94)





(95)





(96)





(97)





(98)





(99)





(100)





(101)





(102)





(103)





(104)





(105)





(106)





(107)





(108)





(109)





(110)





(111)





(112)





(113)





(114)





(115)





(116)





(117)





(118)




(119)




(120)




(121)




(122)




(123)




(124)











(125)





(126)



(127)



(128)




or tautomeric forms, salts, stereoisomers or mixtures thereof in all ratios.

Claims 6-8. (Canceled).

9. (Previously presented) A pharmaceutical composition, comprising one or more of the compound or compounds according to claim 34, or tautomeric forms, salts, stereoisomers or mixtures thereof in all ratios, in a pharmaceutical composition.
10. (Previously presented) The pharmaceutical composition according to claim 9, characterized in that it contains one or more additional compounds, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutical active ingredients.
11. (Previously presented) A process for the manufacture of a pharmaceutical composition, comprising that one or more of the compound or compounds according to claim 34, or tautomeric forms, salts, stereoisomers or mixtures thereof in all ratios, and one or more compound or compounds, selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients other than the compound or compounds according to claim 34, is processed by mechanical means into a pharmaceutical composition that is suitable as dosage form for application and/or administration to a patient.

Claims 12-28. (Canceled).

29. (Previously presented) A method for producing the compound or compounds of claim 34, or tautomeric forms, salts, or stereoisomers thereof, comprising that
  - a) a compound of formula II




wherein

$L^1$  is Cl, Br, I, OH, an esterified OH-group or a diazonium moiety, and  $R^6$ ,  $R^8$ , p and Y are as defined in claim 34,

is reacted

b) with a compound of formula III,



wherein


$L^2$  is H or a metal ion, and  $R^7$ ,  $R^9$ , q, X,  $Ar^2$ ,  $R^{10}$  and r are as defined in claim 34,

and optionally

c) isolating and/or treating the compound or compounds of claim 34, obtained by said reaction with an acid, to obtain the salt thereof.

Claims 30-33. (Cancelled.)

34. (Previously presented) A compound or compounds of formula I



wherein

$\text{Ar}^2$  is pyridinyl or pyrimidyl,

$\text{R}^6$ ,  $\text{R}^7$  independently from one another, are H or unbranched or branched alkyl comprising 1 to 6 carbon atoms, optionally substituted by one or more Hal atoms,

$\text{R}^8$ ,  $\text{R}^9$  independently from one another, are selected from the group consisting of A, H, Hal and unbranched or branched alkyl comprising 1 to 6 carbon atoms, optionally substituted by one or more Hal atoms,

A is selected from the group consisting of alkyl, alkenyl, cycloalkyl, alkylene cycloalkyl, alkoxy and alkoxyalkyl,

$\text{R}^{10}$  is selected from the group consisting of H, alkyl comprising 1 to 4 carbon atoms and  $(\text{CH}_2)_n\text{CONR}^{11}\text{R}^{12}$ ,

$\text{R}^{11}$ ,  $\text{R}^{12}$  independently from one another, are selected from the group consisting of H, Hal and branched or unbranched alkyl comprising 1 to 6

carbon atoms, optionally substituted by one or more Hal atoms,

n is 0, 1, 2, 3, 4, or 5,

X is O or  $\text{CH}_2$ ,

Y is O,

p is 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4,

r is 0, 1, 2 or 3,

and

Hal is selected from the group consisting of F, Cl, Br and I

or tautomeric forms, salts, stereoisomers or mixtures thereof in all ratios.

35. (Currently amended) The compound or compounds according to claim 34,  
wherein

$\text{Ar}^2$  is pyridinyl,

$\text{R}^6$ ,  $\text{R}^7$  independently from one another, are H or are selected from the group  
consisting of methyl, ethyl, trifluoro methyl, pentafluoro ethyl, isopropyl, and  
tert.-butyl,

$\text{R}^8$ ,  $\text{R}^9$  independently from one another, are H or hal Hal or are selected from the

group consisting of methyl, ethyl, trifluoro methyl, pentafluoro ethyl, isopropyl, and tert.-butyl, and,

X is O, and

hal Hal is selected from the group consisting of F, Cl and Br,

or tautomeric forms, salts, stereoisomers or mixtures thereof in all ratios.